Antibe Therapeutics News

Antibe Therapeutics Aktie VALOR 21675228 / ISIN CA0370251039

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

10.04.24	Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act (Businesswire)
09.04.24	Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act (Businesswire)
01.04.24	Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance (Businesswire)
20.03.24	Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting (Businesswire)
07.03.24	Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting (Businesswire)
04.03.24	Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma (Businesswire)
14.02.24	Antibe Reports Q3 2024 Interim Financial and Operating Results (Businesswire)
01.02.24	Antibe Extends Early Warrant Exercise Incentive Program (Businesswire)
29.12.23	Antibe Announces Early Warrant Exercise Incentive Program (Businesswire)
12.12.23	Antibe Therapeutics Announces Amendment to Warrant Terms (Businesswire)
13.11.23	Antibe Reports Q2 2024 Interim Financial and Operating Results (Businesswire)
09.11.23	Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation (Businesswire)
01.11.23	Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation (Businesswire)
18.10.23	Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation (Businesswire)
28.09.23	Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul (Businesswire)
08.09.23	Antibe Announces Results of 2023 Annual Meeting (Businesswire)
14.08.23	Antibe Reports Q1 2024 Interim Financial and Operating Results (Businesswire)
29.06.23	Antibe Reports 2023 Year-End Results and Business Highlights (Businesswire)
25.04.23	Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit (Businesswire)
18.04.23	Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
11.04.23	Antibe Provides April 2023 Corporate Update (Businesswire)
15.02.23	Antibe Reports Q3 2023 Interim Financial and Operating Results (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’022.50	1.89 %	K V
Kuehne+Nagel Int	176.35	1.67 %	K V
ABB	60.16	1.55 %	K V
Sika	165.00	1.54 %	K V
Swisscom	586.50	-0.68 %	K V
Swiss Re	127.55	-1.20 %	K V
Alcon	63.70	-1.33 %	K V
Swiss Life Hldg	892.80	-1.72 %	K V
Zurich Insur Gr	577.80	-1.97 %	K V